DHL Group to spend big on health logistics
The logistics service provider has announced a strategic investment of €2 billion over the next five years to enhance its logistics capabilities in the life sciences and healthcare sector.
THIS INVESTMENT supports the Group’s “Strategy 2030” and reinforces DHL’s commitment to helping healthcare customers grow, innovate, and serve patients more effectively worldwide. With 50% of the investment allocated to the Americas, 25% to Asia Pacific, and 25% to the EMEA region, DHL is expanding its global footprint to deliver integrated, faster, more reliable, and patient-centric logistics solutions wherever healthcare companies operate.
The investment will focus on enhancing high-quality infrastructure and technology across all logistics touchpoints – from storage, order fulfillment, and distribution to global shipping and last-mile delivery.
A significant part of the investment will be allocated to establishing new cross-divisional GPD-certified Pharma Hubs for multi-temperature shipments lanes, expanding cold chain capacity in existing facilities, commissioning new temperature-controlled vehicles, and enhancing both passive and active packaging solutions to ensure sustainable delivery.
In addition to infrastructure investments, DHL Group has recently acquired CRYOPDP, a leading specialty courier focused on clinical trials, biopharma, and cell and gene therapies.
